Outcomes
Of the 14 patients who received VDC-ICE chemotherapy, 8 (57%) achieved
clinical remission (Supplemental Table S2). Eight patients (57%)
experienced relapse or progressive disease, of which 50% had disease at
a new site different than the original sites of disease. At the time of
data collection, 56% (n=5) of patients with MRT were alive (including
both patients with MRT of the kidney), as well as all patients with DAWT
(n=3), CCSK (n=1), and anaplastic chordoma (n=1).